The blockbuster weight-loss drug Ozempic has ignited a ferocious debate over the ethics and efficacy of treating obesity with medication.

Oddly, this intense ideological battle has glossed over perhaps the most important question we should answer: how does the drug impact individual patients? Our Director of Medicine Dr. Chuck Dinerstein is working to correct that oversight by documenting his experience with Ozempic.